ChiefGastrointestinal Oncology Service, Memorial Sloan Kettering Cancer CenterNew York, New York, United States
90: Pathological complete response to FLOT chemotherapy with or without durvalumab in resectable gastric and gastroesophageal junction cancer: subgroup analysis by region from the phase 3, randomized, double-blind MATTERHORN study
Friday, March 22, 202410:42am – 10:52am ET